caa a22 4500 477072321 CHVBK 20180405111429.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00052506 doi (NATIONALLICENCE)springer-10.1007/BF00052506 John Mancini G. Department of Medicine, University of British Columbia, Vancouver, Canada aut Emerging concepts: Angiotensin-converting enzyme inhibition in coronary artery disease [Elektronische Daten] [G. John Mancini] Summary: Angiotensin-converting enzyme (ACE) inhibitors have played a highly beneficial role in the therapy of hypertension and congestive heart failure. Detailed analysis of some of the heart failure trials in patients with these diseases has uncovered unexpected benefits in the prevention of cardiovascular events. Paralleling these observations are the rapidly accruing basic studies describing important molecular and cellular effects of these agents. For example, ACE inhibition will prevent stimulation of smooth muscle cell angiotensin II receptors, thereby blocking both contractile and proliferative actions. In addition, ACE inhibition of kininase II inhibits the breakdown of bradykinin. Bradykinin is a direct stimulant of nitric oxide release from the intact endothelial cell. Thus, at the cellular level ACE inhibition shifts the balance of ongoing mechanisms in favor of those promoting vasodilatory, antiaggregatory, antithrombotic, and antiproliferative effects. These effects underlie the potential benefits of ACE inhibition in the therapy of coronary artery disease and atherosclerosis. Kluwer Academic Publishers, 1996 angiotensin converting enzyme inhibitor nationallicence endothelial function nationallicence coronary artery disease nationallicence Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 609-612 0920-3206 10<609 1996 10 10557 https://doi.org/10.1007/BF00052506 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00052506 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- John Mancini G. Department of Medicine, University of British Columbia, Vancouver, Canada aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10(1996-11-01), 609-612 0920-3206 10<609 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer